Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

181. [Pembrolizumab (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V ]

[Pembrolizumab (non-small cell lung cancer) - benefit assessment according to õ35a Social Code Book V ] Pembrolizumab (nicht kleinzelliges Lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-06 [Pembrolizumab (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V ] Pembrolizumab (nicht kleinzelliges Lungenkarzinom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-06 [Pembrolizumab (non-small cell lung cancer (...) ; auftrag A17-06. [Pembrolizumab (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V ] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 509. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Humans Language Published German Country of organisation Germany English summary There is no English language

Health Technology Assessment (HTA) Database.2017

182. [Nintedanib in lung cancer]

[Nintedanib in lung cancer] [Nintedanib in lung cancer] [Nintedanib in lung cancer] González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Nintedanib in lung (...) cancer] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 538. 2017 Authors' conclusions Moderate quality evidence showed that adding nintedanib to chemotherapy with docetaxel or pemetrexed as second-line regimens would not improve overall survival or quality of life of advanced lung cancer patients. Low quality evidence reports that the use with docetaxel in patients with adenocarcinoma

Health Technology Assessment (HTA) Database.2017

183. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 (...) tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level

NEJM2017

184. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. Methods In a randomized, open

NEJM2017

186. Brigatinib (Alunbrig) - anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) Alunbrig (brigatinib) Tablets U.S. Department of Health and Human Services Search FDA Submit search Alunbrig (brigatinib) Tablets Alunbrig Company: ARIAD Pharmaceuticals, Inc. Application No.: 208772 Approval Date: 04/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2017

187. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials 28319436 2017 03 20 2017 05 19 1527-7755 35 15 2017 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. 1641-1649 10.1200/JCO.2016.72.0722 (...) Purpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer

EvidenceUpdates2017

188. Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer

Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer May 2017 Technology Description: Rovalpituzumab tesirine is a new antibody‐drug conjugate that binds to delta‐like protein 3(DLL3) present (...) in the cancer cells of most small cell lung cancer patients. This drug works by attacking and killing cancer cells, limiting the growth of tumours due to small cell lung cancer (SCLC). This drug is being currently studied as third line therapy for patients that get worse after treatment with other therapies such as chemotherapy or radiotherapy. Specialty You may also be interested in: Apr 2015 Specialty: Apr 2015 Specialty: Apr 2015 Specialty: Please answer these 2 questions to proceed to your free download

NIHR Innovation Observatory2017

189. Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current of former smokers) non-small cell lung cancer

Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current of former smokers) non-small cell lung cancer Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current of former smokers) non-small cell lung cancer ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current of former smokers (...) ) non-small cell lung cancer May 2017 Technology Description: Veliparib is being developed as an improvement on previous drugs, for the treatment of advanced or metastatic non-squamous non-small cell lung cancer. In combination with carboplatin and paclitaxel it will, if licenced, offer an additional treatment option for patients with this indication. Specialty You may also be interested in: Apr 2015 Specialty: Apr 2015 Specialty: Apr 2015 Specialty: Please answer these 2 questions to proceed

NIHR Innovation Observatory2017

190. Alecensaro for Non-Small Cell Lung Cancer (with CNS metastases) – Details

Alecensaro for Non-Small Cell Lung Cancer (with CNS metastases) – Details Alecensaro for Non-Small Cell Lung Cancer (with CNS metastases) – Details | CADTH.ca Find the information you need Alecensaro for Non-Small Cell Lung Cancer (with CNS metastases) – Details Alecensaro for Non-Small Cell Lung Cancer (with CNS metastases) – Details Project Number pCODR 10092 Brand Name Alecensaro Generic Name Alectinib Strength 150 mg capsule Tumour Type Lung Indication Non-Small Cell Lung Cancer (with CNS (...) metastases) Funding Request As monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib and have CNS metastases Review Status Under Review Pre Noc Submission No NOC Date September 29, 2016 Manufacturer Hoffmann-La Roche Limited Submitter Hoffmann-La Roche Limited Submission Date October 3, 2016 Submission Deemed Complete October 11, 2016 Submission Type

CADTH - Pan Canadian Oncology Drug Review2017

191. Tagrisso for Non-Small Cell Lung Cancer – Details

Tagrisso for Non-Small Cell Lung Cancer – Details Tagrisso for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell Lung Cancer – Details Tagrisso for Non-Small Cell Lung Cancer – Details Project Number pCODR 10076 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tablets Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced or metastatic EGFR T790M

CADTH - Pan Canadian Oncology Drug Review2017

192. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. BACKGROUND: Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer. Given those promising results, we did a phase 3 trial to directly compare the efficacy and safety (...) of alectinib and crizotinib. METHODS: J-ALEX was a randomised, open-label, phase 3 trial that recruited ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer, who were chemotherapy-naive or had received one previous chemotherapy regimen, from 41 study sites in Japan. Patients were randomly assigned (1:1) via an interactive web response system using a permuted-block method stratified by Eastern Cooperative Oncology Group performance status, treatment line, and disease stage

Lancet2017

193. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. Importance: There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer. Objective: To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel (...) . Adverse events of grade 3 or higher were more frequent with selumetinib + docetaxel (169 adverse events [67%] for selumetinib + docetaxel vs 115 adverse events [45%] for placebo + docetaxel; difference, 22%). Conclusions and Relevance: Among patients with previously treated advanced KRAS-mutant non-small cell lung cancer, addition of selumetinib to docetaxel did not improve progression-free survival compared with docetaxel alone. Trial Registration: clinicaltrials.gov: NCT01933932 .

JAMA2017

194. Ceritinib (lung cancer): Addendum to Commission A16-62

Ceritinib (lung cancer): Addendum to Commission A16-62 Ceritinib (nicht kleinzelliges Lungenkarzinom): Addendum zum Auftrag A16-62; Auftrag A17-05 [Ceritinib (lung cancer): Addendum to Commission A16-62] Ceritinib (nicht kleinzelliges Lungenkarzinom): Addendum zum Auftrag A16-62; Auftrag A17-05 [Ceritinib (lung cancer): Addendum to Commission A16-62] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ceritinib (nicht kleinzelliges Lungenkarzinom): Addendum zum Auftrag A16-62; Auftrag A17-05. [Ceritinib (lung cancer): Addendum to Commission A16-62] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 490. 2017 Final publication URL Indexing Status Subject indexing

Health Technology Assessment (HTA) Database.2017

195. Proton beam therapy for non-small cell lung cancer

Proton beam therapy for non-small cell lung cancer Proton beam therapy for non-small cell lung cancer Proton beam therapy for non-small cell lung cancer HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Proton beam therapy for non-small cell lung cancer. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Proton beam (...) of radiation therapy relative to conventional photon or electron beam radiation therapy, potentially reducing the undesirable adverse events that can occur during and after radiation therapy for lung cancer, particularly, non-small cell lung cancer (NSCLC). Controversy: Highly sophisticated methods have been developed for targeting conventional radiation therapy, including dose fractionation, modulation of radiation intensity, and delivery of radiation with devices that sweep in multiple arcs around

Health Technology Assessment (HTA) Database.2017

196. Alectinib hydrochloride (Alecensa) - As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.

Alectinib hydrochloride (Alecensa) - As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib. Published 08 May 2017 Statement of Advice: alectinib hydrochloride (Alecensa ® ) 150mg hard capsules (No: 1257/17) Roche Products Ltd 07 April 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation alectinib hydrochloride (Alecensa ® ) is not recommended for use (...) within NHS Scotland. Indication under review: As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice

Scottish Medicines Consortium2017

197. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial

Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial 28377492 2017 04 05 2017 04 05 1468-3296 2017 Apr 04 Thorax Thorax Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. thoraxjnl-2016-209825 10.1136/thoraxjnl-2016-209825 ITALUNG is contributing to the European evaluation of low-dose CT (LDCT) screening for lung cancer (LC). Eligible subjects aged 55-69 years, smokers or ex-smokers (at least 20 pack-years (...) , ISPO-Cancer Research and Prevention Institute, Florence, Italy. Carozzi Francesca M FM Prevention Laboratory Unit, ISPO-Cancer Research and Prevention Institute, Florence, Italy. Mascalchi Mario M Radiodiagnostic Section, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. and the ITALUNG Working Group eng Journal Article 2017 04 04 England Thorax 0417353 0040-6376 Clinical Epidemiology Lung Cancer Paci Eugenio E Puliti Donella D Zappa Marco M

EvidenceUpdates2017

198. Tracking the Evolution of Non-Small-Cell Lung Cancer.

Tracking the Evolution of Non-Small-Cell Lung Cancer. Background Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome and to determine the clonal nature of driver events and evolutionary processes in early-stage NSCLC. Methods In this prospective cohort study, we performed multiregion (...) whole-exome sequencing on 100 early-stage NSCLC tumors that had been resected before systemic therapy. We sequenced and analyzed 327 tumor regions to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between intratumor heterogeneity and recurrence-free survival. Results We observed widespread intratumor heterogeneity for both somatic copy-number alterations and mutations. Driver mutations in EGFR, MET, BRAF, and TP53 were almost always clonal

NEJM2017

199. Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated

Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated April 2017 Technology Description: Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells (...) . Pembrolizumab targets and blocks a protein called PD‐L1 on the surface of certain immune cells called T‐cells. Blocking the PD‐L1 protein triggers the T‐cells to find and kill cancer cells. It is administered as a drip into a vein for 30 minutes every three weeks for up to 35 cycles. Clinical trials suggest that when treated with pembrolizumab as opposed to platinum‐based chemotherapies, those advanced NSCLC patients who have not yet received treatment (treatment naïve) may survive for longer and achieve

NIHR Innovation Observatory2017

200. Surgery for limited-stage small-cell lung cancer.

Surgery for limited-stage small-cell lung cancer. BACKGROUND: Current treatment guidelines for limited-stage small-cell lung cancer (SCLC) recommend concomitant platinum-based chemo-radiotherapy plus prophylactic cranial irradiation, based on the premise that SCLC disseminates early, and is chemosensitive. However, although there is usually a favourable initial response, relapse is common and the cure rate for limited-stage SCLC remains relatively poor. Some recent clinical practice guidelines (...) undergoing radiotherapy are likely to experience more dyspnoea. This was measured using a non-validated scale. AUTHORS' CONCLUSIONS: Evidence from currently available RCTs does not support a role for surgical resection in the management of limited-stage small-cell lung cancer; however our conclusions are limited by the quality of the available evidence and the lack of contemporary data. The results of the trials included in this review may not be generalisable to patients with clinical stage 1 small-cell

Cochrane2017